PFE - Vaxart's oral COVID-19 vaccine shows potential to offer promising solution against variants

New data obtained from Vaxart's (VXRT) Phase I COVID-19 trial suggests that its oral coronavirus vaccine, VXA-CoV2-1, triggers mucosal immunity, includes both S and N SARS-Cov-2 proteins, and has broad cross-coronavirus activity. phase I data were compared to the data from volunteers subsequently vaccinated with the Moderna (MRNA) or Pfizer (PFE) mRNA vaccine and suggest that the same may be true against coronavirus. In a presentation, Dr. Sean Tucker, Chief Scientific Officer discussed:Vaxart’s vaccine candidate showed higher CD8+ T-cell responses than the Pfizer and Moderna vaccines, which is correlated to protection against COVID disease.The Vaxart vaccine candidate elicited a T-cell response against SARS-Cov-2, as well as showed cross-reactivity against diverse coronaviruses.N protein responses to SARS-CoV-1 have been shown to last 17 years after infection and cross-react to SARS-CoV-2.Vaxart’s vaccine candidate triggered specific IgA antibodies in the mucosa which appeared to be cross-reactive against other coronaviruses and the endemic common cold viruses.CD8+ T-cells produced by

For further details see:

Vaxart's oral COVID-19 vaccine shows potential to offer promising solution against variants